In Section A, members will receive different doses and schedules of oral ABBV-744 tablet to establish Secure dosing routine. Supplemental individuals are going to be enrolled in the determined monotherapy dosign routine. In Segment B, individuals will get oral ruxolitinib and ABBV-744 will be provided as "insert-on" therapy. In Phase https://abbv-744-brd4-inhibitor-m91346.izrablog.com/32504504/indicators-on-clinical-trial-recruitment-for-abbv-744-study-you-should-know